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Abstract
Patients with deletions on chromosome 9q31.2 may exhibit delayed puberty, craniofacial phenotype including cleft 
lip/palate, and olfactory bulb hypoplasia. We report a patient with congenital HH with anosmia (Kallmann syndrome, 
KS) and a de novo 2.38 Mb heterozygous deletion in 9q31.2. The deletion breakpoints (determined with whole-
genome linked-read sequencing) were in the FKTN gene (9:108,331,353) and in a non-coding area (9:110,707,332) 
(hg19). The deletion encompassed six protein-coding genes (FKTN, ZNF462, TAL2, TMEM38B, RAD23B, and KLF4). ZNF462 
haploinsufficiency was consistent with the patient’s Weiss–Kruszka syndrome (craniofacial phenotype, developmental 
delay, and sensorineural hearing loss), but did not explain his KS. In further analyses, he did not carry rare sequence 
variants in 32 known KS genes in whole-exome sequencing and displayed no aberrant splicing of 15 KS genes that 
were expressed in peripheral blood leukocyte transcriptome. The deletion was 1.8 Mb upstream of a KS candidate 
gene locus (PALM2AKAP2) but did not suppress its expression. In conclusion, this is the first report of a patient with 
Weiss–Kruszka syndrome and KS. We suggest that patients carrying a microdeletion in 9q31.2 should be evaluated for 
the presence of KS and KS-related features.
Introduction
Congenital hypogonadotropic hypogonadism (CHH) is a 
rare genetic disease that prevents pubertal development 
and elicits infertility due to deficient secretion or action 
of gonadotropin-releasing hormone (GnRH) (1). CHH is 
called normosmic (nCHH) if the patient has a normal 
sense of smell, and Kallmann syndrome (KS) if the patient 
has an absent or deficient ability to smell (1). Both nCHH 
and KS may manifest with accompanying anomalies, 
such as bone abnormalities, hearing impairment and ear 
abnormalities, cleft lip or palate, and anophthalmia and/
or coloboma (1). These diseases present wide phenotypic 
and genetic heterogeneity, as over 60 genes underlying 
nCHH and KS have been identified to date (1, 2). However, 
several nCHH and KS genes remain to be discovered, since 
the currently known genes account for only half of all 
cases (1). nCHH and KS might be inherited in a Mendelian 
or oligogenic fashion depending on the causative gene; 
large cohort studies suggest that a significant proportion 
of the cases are oligogenic (1).
Recently, Weiss and Kruszka reported a series of 
patients with developmental delay, distinct craniofacial 
phenotypes, and hearing loss and showed that this 
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syndrome is due to loss-of-function ZNF462 mutations or 
microdeletions in the 9q31.2 area (3). We report a patient 
with a complex phenotype including Weiss–Kruszka 
syndrome, KS, and a de novo deletion on chromosome 
9q31.2. The deletion encompassed ZNF462, FKTN, TAL2, 
TMEM38B, RAD23B, and KLF4. To date, 25 patients with 
Weiss–Kruszka syndrome have been reported (3, 4, 5, 6), 
yet delayed puberty, anosmia, or CHH are not among the 
listed phenotypic features. On the other hand, deletions 
in the 9q31.2 chromosomal area have been continuously 
described since the 1970s (7, 8, 9, 10, 11, 12, 13, 14, 15), at 
least one of whom had CHH (11), olfactory bulb hypoplasia 
(14), or delayed puberty in multiple family members (15), 
and at least four had cleft lip or palate (8, 10, 13, 14), 
that is, phenotypic features reminiscent of KS. However, 
no clear link between the 9q31.2 deletions and complete 
KS currently exists. The closest connection comes from 
disruption or pathogenic variants in the closely located 
PALM2AKAP2 locus. Indeed, PALM2 and AKAP2, which 
can form fusion transcripts, constitute potential KS 
disease genes, since a female with KS and Graves’ disease 
carried a missense mutation, which was predicted to be 
deleterious, in PALM2 (16), and a male with KS and bone 
anomalies carried a balanced chromosomal translocation 
that disrupted AKAP2 expression (17).
To investigate the putative relationship between 
the proband’s 9q31.2 deletion and KS, we first defined 
the exact deletion breakpoints with linked-read whole-
genome sequencing. Next, we investigated if the deletion 
was associated with decreased expression of PALM2AKAP2 
and screened this gene in a set of Finnish KS patients. 
Since these investigations did not support the connection 
between PALM2AKAP2 and KS, we performed whole-
exome and RNA sequencing in the proband and his 
family members to exclude defects in genes implicated 
in KS and to reveal potential new candidate genes. Our 
results, together with the CHH and KS-related phenotypes 
in previous patients with 9q31.2 deletions suggest that 
microdeletions in this chromosomal region underlie KS.
Subjects and methods
Subjects
We investigated a Finnish family whose son (the 
proband) had been assessed for delayed development and 
subsequently for the absence of puberty. He was the second 
child of healthy nonconsanguineous parents (Fig. 1), 
and he had a healthy sister, who had normal timing of 
puberty since she reached menarche at the age of 12 
years. The mother’s menarche age had been 11 years, and 
the father had no reported history of delayed puberty. 
Following an uneventful pregnancy, the proband was 
born at gestation week H42+1. His birth weight was 3240 
g and his length was 50 cm. He received 4, 6, and 9 Apgar 
points at the ages of 1, 5, and 10 min, respectively. He was 
noted to have a muscular ventricular septal defect that 
closed spontaneously. His testes were normally descended. 
Before going to school, he was diagnosed with attention 
deficit disorder and mild developmental delay. He had 
distinctive facial features including ptosis, flat nasal tip, 
low set ears, and mild bilateral sensorineural hearing loss 
with normal semicircular canals in MRI. At the age of 6.5 
years, he underwent comparative genetic hybridization 
(Agilent 44K), in which a 2.38 Mb deletion in the 9q31.2 
area was detected, yet the precise breakpoints remained 
undetermined. The deletion was de novo, as his parents 
tested negative for the presence of the deletion.
At the age of 13.5 years, the proband was referred 
for the evaluation of delayed puberty and was noted 
to have a hypoplastic scrotum and testes. He had self-
reported anosmia, which had been well appreciated in 
the family and absent olfactory bulbs in the MRI. He had 
no synkinesia, hand or foot deformities, pigmentation 
defects or missing teeth, nor he reported problems with 
balance. Abdominal ultrasound revealed two kidneys. 
His circulating reproductive hormone levels were low 
Figure 1
Pedigree of the family, in which the proband (arrow) carried a 
heterozygous de novo 2.38 Mb deletion in chromosome 9q31.2 
that encompassed FKTN, TAL2, TMEM38B, ZNF462, RAD23B, and 
KLF4. The proband had Weiss–Kruszka syndrome due to ZNF462 
haploinsufficiency with ptosis, flat nasal tip, low set ears, mild 
developmental delay, and mild bilateral sensorineural hearing 
loss, and Kallmann syndrome (congenital hypogonadotropic 
hypogonadism, anosmia, and the absence of olfactory bulbs).
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(LH 0.1 IU/L, FSH 0.2 IU/L, testosterone 0.7 nM, and 
inhibin B level was very low, 14 ng/L). At the age of 14 
years and 11 months, he was still prepubertal (Tanner 
stage G1) with pubic hair stage P3. His testes were very 
small, only 1 cm in length (corresponding to < 1 mL). 
His reproductive hormone levels were still low; serum 
LH 0.1 IU/L, inhibin B 23 ng/L, and testosterone 0.4 nM. 
Based on the very small testicular size, low reproductive 
hormone and inhibin B levels, anosmia, and the absence 
of olfactory bulbs in the MRI scan, he was prepubertal, 
and a diagnosis of Kallmann syndrome was set (1, 18). 
Induction of his puberty with low-dose testosterone 
was commenced. During the treatment, his testis size 
remained extremely small (assessed at the age of 16 years 
and 9 months) in the setting of low gonadotropin and 
inhibin B (23 ng/L at the age of 15 years and 9 months; 
29 ng/L at 16 years 9 months, and 28 ng/L at 17 years 
7 months) levels consistent with the KS diagnosis. As a 
part of the diagnostic procedure, he underwent BluePrint 
Genetics® Kallmann Syndrome Panel Plus (version 3), a 
diagnostic platform that covers the coding regions of the 
following genes: ANOS1, CHD7, FGF8, FGFR1, GNRHR, 
KISS1R, PROK2, PROKR2, and TACR3 up to 20 bp of the 
intronic sequence with single nucleotide changes, small 
indels up to 220 bp, and copy number variations defined 
as single exon or larger deletions and duplications.
Determination of the deletion breakpoints and 
presence of structural variants in KS genes with 
whole-genome linked-read sequencing
DNA of all family members was extracted from peripheral 
blood leukocytes (PBL). The proband and parent RNA were 
isolated with the QIAamp RNA Blood Mini Kit (QIAGEN) 
from PBLs. The whole-genome linked-read sequencing 
of the proband was performed at FIMM (Institute for 
Molecular Medicine Finland) according to 10× Genomics 
Chromium library preparation (Chromium Genome 
Reagent Kits v2 RevB; 10× Genomics, Pleasanton, CA, 
USA). The sample was sequenced with NovaSeq 6000 
system (Illumina Inc., San Diego, CA, USA) using S4 flow 
cell and XP workflow. Read length for the paired-end 
run was 2×151. The reads were aligned to the GRCh37 
(hg19) reference genome. The data were analyzed with 
Longranger 2.2.2 WGS pipeline with default parameters 
and GATK for variant calling and visualized with Loupe 
2.1.1 (both programs by 10× Genomics). The genome was 
covered with a mean depth of 34.7×, and a mean molecule 
length of 26.8 kb. Loupe interactive visualization tool 
2.1.1 was employed to define the exact 9q31.2 deletion 
breakpoints. In addition, as MLPA (multiplex ligation-
dependent probe amplification) is available for only a 
fraction of known KS genes, we verified the absence of 
genomic structural variants of over 40 bp in size in the 
coding regions of 32 known KS genes (ANOS1, FGFR1, 
FGF8, FGF17, PROK2, PROKR2, CHD7, NSMF, HS6ST1, 
WDR11, SEMA3A, SEMA7A, PLXNA1, SOX10, IL17RD, 
FEZF1, NDNF, TCF12, TUBB3, DCC, SMCHD1, KLB, NTN1, 
SPRY4, PTCH1, FLRT3, AMH, DUSP6, PLXNA3, NRP1, 
SPRY2, and NRP2) with Loupe 2.1.1.
Investigation of PALM2AKAP2 expression 
with RT-qPCR
The RNA extracted from the proband and his parents were 
converted into cDNA using the iScript cDNA Synthesis Kit 
(Bio-Rad) according to the manufacturer’s instructions 
in a regular thermocycler with 1 µg of total RNA. The 
synthesized cDNAs were used as templates to assess the 
mRNA expression with a ready-to-use qPCR mix (Solis 
Biodyne) in a quantitative PCR machine (Roche LC480 II). 
The expression levels of PALM2AKAP2 were normalized to 
GAPDH. The relative expression levels were standardized 
against a healthy unrelated control sample, which was 
given an arbitrary value of 1.0. The PCR conditions and 
primers are available on request.
Sanger sequencing of PALM2AKAP2 in Finnish 
Kallmann syndrome patients
We examined a set of 16 Finnish KS patients (15 men, 1 
woman) without mutations in ANOS1, FGFR1, FGF8, 
PROK2, PROKR2, CHD7, and WDR11 (19, 20). The exons 
and exon-intron boundaries of PALM2 (NC_000009.11, 
NM_053016.6, GRCh37) and AKAP2 (NC_000009.11, 
NM_001198656.1, GRCh37) were amplified with PCR 
from the genomic DNA. The PCR conditions and primers 
are available upon request. The PCR products were 
purified with ExoProStar treatment (GE Healthcare Life 
Sciences), and sequenced from both directions using the 
ABI BigDyeTerminator Cycle Sequencing Kit (v3.1) and 
ABI Prism 3730xl DNA Analyzer automated sequencer 
(Applied Biosystem). The DNA sequences were aligned 
and read with Sequencher® 4.9 software (Gene Codes 
Corporation, AnnArbor, MI, USA). As one of the patients 
harbored a variant NC_000009.11:g.112918586C>T, in 
intron 2 of AKAP2, his RNA was converted into cDNA 
by using the SuperScript® III First-Strand Synthesis 
System for RT-PCR kit (Invitrogen by Life Technologies) 
according to the manufacturer’s instructions. Part of 
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the AKAP2 transcript was PCR-amplified with cDNA-
specific primers and subsequently sequenced. Effect of 
the AKAP2 variant NC_000009.11:g.112918586C>T was 
also predicted with Human Splicing Finder (https://www.
genomnis.com/access-hsf) (21), MutationTaster (http://
www.mutationtaster.org/) (22), NetGene2 (http://www.cbs.
dtu.dk/services/NetGene2/) (23, 24), and BDGP NNSPLICE 
(https://www.fruitfly.org/seq_tools/splice.html) (25), and 
its clinical interpretation was performed with InterVar 
(http://wintervar.wglab.org/) (26).
Whole-exome sequencing
The whole-exome sequencing (WES) of the proband’s 
family was performed with Illumina Novaseq S2 PE100 
technology. First, the adapter was trimmed from the 
reads, as well as any low-quality nucleotides from the 
5’ or 3’ ends of the read, removing pairs with less than 
36 bp. The reads were aligned to the GRCh37 (hg19) 
reference genome with the BWA (Burrows–Wheeler 
Aligner). Non-unique read pairs and non-unique single 
reads were removed and GATK Base Recalibrator was used 
to clean the alignment. Any potential PCR duplicates 
were removed using Picard MarkDuplicates, and GATK 
IndelRealigner was used for indel sites. The mpileup from 
the SAMTOOLS package was used for variant calling (27). 
The sequencing yielded a mean target coverage of 222× 
and 98% of 20× coverage.
Data analysis
First, we verified that the coding exons of 32 KS-associated 
genes (ANOS1, FGFR1, FGF8, FGF17, PROK2, PROKR2, 
CHD7, NSMF, HS6ST1, WDR11, SEMA3A, SEMA7A, 
PLXNA1, SOX10, IL17RD, FEZF1, NDNF, TCF12, TUBB3, 
DCC, SMCHD1, KLB, NTN1, SPRY4, PTCH1, FLRT3, AMH, 
DUSP6, PLXNA3, NRP1, SPRY2, and NRP2) were covered 
in WES by using the BasePlayer analysis and visualization 
tool (28). Subsequently, the proband’s VCP file, provided 
by FIMM (27), was annotated using ANNOVAR (https://
doc-openbio.readthedocs.io/projects/annovar/en/
latest/). We defined that a potentially causative variant 
should be in the consensus splice-site or it should be 
nonsynonymous and not classified as benign by any of 
the ten applied in silico tools (SIFT, LRT, MutationTaster, 
MutationAssessor, FATHMM, PROVEAN, MetaSVM, 
MetaLR_pred, M-CAP, and fathmm-MKL). Additionally, 
a potentially causative variant(s) should (i) occur only 
in the proband (de novo) (and have a minor allele 
frequency MAF <0.1%); (ii) be biallelic (autosomal 
recessive inheritance) (MAF <2%); (iii) be monoallelic 
and inherited from one parent and be absent in the 
sister (autosomal dominant) (MAF <0.1%); or (iv) 
be monoallelic and inherited in the X chromosome 
(X-linked recessive) (MAF <2%). The frequency criteria 
were applied for all ethnic subpopulation frequencies 
in gnomAD, ExAC, 1000 Genomes, and Exome Variant 
Server (provided in the ANNOVAR annotation) and 
in dbSNP (https://www.ncbi.nlm.nih.gov/snp/) (29) 
(manually verified). Finally, to be accepted for further 
analyses, a potentially causative variant in WES had 
to be present in the RNA sequencing data and/or the 
linked-read WGS data. We confirmed the genotype 
and segregation of the two such variants in all family 
members with Sanger sequencing. The primers were 
designed for sequences around candidate variants in 
RIMBP3C (NC_000022.10, NM_001128633.2) and SARS1 
(NC_000001.10, NM_006513.4) (GRCh37). The PCR 
conditions and primers are available upon request.
RNA sequencing
The quality and integrity of the RNA were assessed with 
high sensitivity D5000 Screen Tape® System (Agilent). 
Following the quality control, RNASeq libraries were 
prepared using NEBNext Ultra II Directional Poly (A) 
Capture Kit. RNA sequencing was carried out as paired-
end sequencing with Illumina NextSeq 500 Mid Output 
System. RNA quality-testing, library preparation, and 
sequencing were performed in the Functional Genomics 
Unit (FUGU) at the University of Helsinki, Finland.
RNA-sequencing data analysis
Raw adaptor-trimmed FASTQ files were subjected to 
quality assessment with the FASTQC tool (Simon Andrews, 
Babraham Bioinformatics). Based on the overall data 
quality and the individual reads, additional trimming was 
unnecessary. The sequences were aligned to the GRCh37 
human genome version with the STAR package (30). 
Splicing events of known KS genes were visually verified 
with the Sashimi plot feature of the MISO framework (31) 
in the IGV browser from Broad Institute (32).
Statistics and the probability estimate for the 
occurrence of a 9q31.2 microdeletion and KS
The relative expression values of PALM2AKAP2 in the 
PBLs of the proband (n = 4) and his parents (n = 4) were 
compared with one-way ANOVA, and followed by Tukey’s 
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HSD post-hoc analysis. P-value < 0.05 was accepted to 
indicate statistical significance. To evaluate the role of the 
9q31.2 microdeletion in our proband, we utilized the CNV 
data obtained from the UK Biobank (33, 34, 35), in which 4 
deletions, 1 Mb or larger in size, in a set of 472 734 people, 
overlapped the 24 Mb region, which is depicted with a 
rectangle on chromosome 9 in Fig. 2 (chr9:102,253,143–
126,253,089, GRCh37). Thus, the estimated probability for 
our proband not to harbor a causal mutation in known KS 
genes and to carry such a microdeletion by chance would 
be very small (1:2 × 4:472 734 = 4.23e-06). Moreover, 
at the population level, the probability to encounter a 
Finnish male with KS (incidence 1:30 000) (19) without a 
causative mutation in KS genes, who would carry such a 
microdeletion would be even several magnitudes smaller 
(i.e. 1:30 000 × 1:2 × 4:472 734 = 1.41e-10).
Results
We investigated the genetic and phenotypic features of a 
patient with KS and Weiss–Kruszka syndrome who carried 
a 2.38 Mb deletion on chromosome 9q31.2. A diagnostic-
targeted sequencing panel for KS that covered the coding 
exons of genes ANOS1, CHD7, FGF8, FGFR1, GNRHR, 
KISS1R, PROK2, PROKR2, and TACR3 up to 20 bp intronic 
sequence and structural variants was negative for likely 
pathogenic variants.
Determination of the 9q31.2 deletion breakpoints
To define the exact deletion breakpoints, we performed 
a whole-genome linked-read sequencing of the proband’s 
DNA. He carried a 2.38 Mb deletion on chromosome 
9:108,331,353–110,707,332, excluding PALM2AKAP2 
locus that is located at 9:112,542,589–112,934,792 (hg19) 
(Fig. 2). Instead, the deletion disrupted FKTN, which 
contains ten exons, at 9:108,331,353 in the first intron, 
and no other known gene at 9:110,707,332. The deletion 
encompassed six protein-coding genes (FKTN, TAL2, 
TMEM38B, ZNF462, RAD23B, and KLF4), none of which 
has been implicated in KS.
Figure 2
Schematic representation of the proband’s 
9q31.2 deletion in relation to other 
informative patients with deletions 
encompassing this area. The dashed 
vertical lines indicate our proband’s 2.38 
Mb deletion (chr9:108,331,353–
110,707,332) (hg19), which encompassed 
six protein-coding genes (FKTN, TAL2, 
TMEM38B, ZNF462, RAD23B, and KLF4). 
Rectangles indicate relative locations and 
sizes of deletions in various patients, their 
colors and patterns highlight important 
Kallmann syndrome-related phenotypes 
and the vertical line indicates a Kallmann 
syndrome candidate gene locus 
(PALM2AKAP2). A summary of the patients 
is presented in Supplementary Table 2. 
The figure is modified from (14). The 
deletion coordinates are presented as 
GRCh37 (hg19). For Kulharya  et al. (patient 
2), Chien  et al., and Ramineni et al. 
patients the UCSC genome coordinate 
conversion tool https://genome.ucsc.edu/
cgi-bin/hgLiftOver was employed to 
convert hg18 coordinates to hg19.
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PALM2AKAP2 expression in peripheral 
blood leukocytes
Given that PALM2AKAP2 has been implicated in KS 
and our proband’s deletion laid approximately 1.8 
Mb upstream of the PALM2AKAP2 locus (Fig. 2), we 
investigated whether the expression of PALM2AKAP2 
was altered in peripheral blood leukocyte RNA. However, 
the proband’s PALM2AKAP2 transcript was expressed at a 
higher level than in the father (Fig. 3), indicating that the 
deletion does not suppress PALM2AKAP2 expression.
Sanger sequencing of PALM2 and AKAP2 in 16 
Finnish KS patients
To further probe the possible role of PALM2AKAP2 in KS, 
we screened the coding exons and exon-intron boundaries 
of both PALM2 and AKAP2 in 16 Finnish KS patients 
without mutations in established KS-causing genes (19, 
20). In the intron 2 of AKAP2, we found one heterozygous 
variant, NC_000009.11:g.112918586C>T (rs777796314), 
with a frequency of 0.00004267 in Finns (gnomAD, 
https://gnomad.broadinstitute.org/) (36). This variant was 
classified as likely benign according to the 2015 ACMG/
AMP guidelines (InterVar, (http://wintervar.wglab.org/)) 
(26). The carrier was diagnosed with KS at the age of 14 
years. He had sensorineural hearing loss in the right ear, 
micropenis, normal MRI, and alopecia at the age of 5. He 
had no family history of delayed puberty. Given that two 
out of four in silico tools predicted the variant to affect the 
acceptor site of exon 3 (MutationTaster: disease-causing; 
NetGene2: alteration of acceptor sites), we confirmed in 
vitro that the splicing was normal (data not shown). All 
other encountered PALM2 and AKAP2 variants had MAFs 
above 1% among gnomAD Finns.
Whole-exome sequencing, RNA sequencing, 
splicing analysis, and identification of potentially 
causative variants
Given that the targeted KS gene panel, the deletion in 
9q31.2 per se, or the adjacent candidate gene PALM2AKAP2 
provided no equivocal answer to our question of whether 
this deletion underlies KS in the proband, we sequenced 
the whole exome in the proband, his healthy parents and 
sister. First, no rare sequence variants were found in the 
32 genes implicated in KS (IL17RD, SPRY2, DUSP6, CHD7, 
FGFR1, SOX10, ANOS1, FGF8, FGF17, PROK2, PROKR2, 
NSMF, HS6ST1, WDR11, SEMA3A, SEMA7A, PLXNA1, 
FEZF1, NDNF, TCF12, TUBB3, DCC, SMCHD1, KLB, NTN1, 
SPRY4, PTCH1, FLRT3, AMH, PLXNA3, NRP1, and NRP2). 
Secondly, we investigated in the linked-read WGS data 
whether the proband carried genomic structural variants 
of over 40 bp in the coding regions of these 32 KS genes. 
However, none of the genes were disrupted by structural 
variants. As WES may not detect non-coding variants that 
affect splicing, we investigated the splicing events of KS 
genes in the proband and his parents with RNA sequencing 
and subsequent visualization of transcripts. Overall, 15 
KS genes, FGFR1, PROK2, CHD7, NSMF, HS6ST1, WDR11, 
SEMA3A, SEMA7A, PLXNA1, TCF12, SMCHD1, PTCH1, 
and DUSP6, were expressed in PBLs, and none of them 
displayed aberrant splicing events (data not shown). Finally, 
we investigated whether the WES data would contain new 
potential KS candidate gene mutations. Two rare variants 
of uncertain significance emerged, one in RIMBP3C and 
the other in SARS1. An overview of the variants is shown 
in Supplementary Table 1 and Supplementary Material 
Figure 3
Relative expression of PALM2AKAP2 in the peripheral blood 
leukocytes of the proband with Kallmann syndrome, Weiss–
Kruszka syndrome, and a heterozygous de novo deletion in 
9q31.2, and his healthy parents. The bars represent four 
replicates of PALM2AKAP2 expression measured by qPCR, 
normalized by a housekeeping gene (GAPDH), and adjusted 
against an unrelated control sample. *P < .05 (ANOVA followed 
by Tukey HSD post-hoc analysis).
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(see section on supplementary materials given at the end 
of this article).
Overlapping genetic region with our proband and 
the previously reported patient with CHH
Our proband’s deletion (9:108,331,353-110,707,332) and 
the deletion of the previously described patient with 
CHH (9:110,672,051–120,997,503) (11) overlapped in 
9:110,672,051–110,707,332 (hg19). This region contained 
ribosomal pseudogene RNA5SP293. According to the 
UCSC Genome Browser (https://genome.ucsc.edu/), 
the following transcription factors were determined to 
have binding sites in this overlapping region: GATA3, 
MYC, JUND, CEBPB, TEAD4, GATA2, MAFF, USF2, USF1, 
BHLHE40, ZNF143, ATF3, and SIX5.
Discussion
We report a patient with KS, developmental delay, ptosis, 
ventral septal defect, craniofacial phenotype, and mild 
bilateral sensorineural hearing loss without coding 
region mutations in the established KS genes, which was 
assessed by using a targeted sequencing panel, linked-read 
whole-genome sequencing, RNA sequencing, and WES. 
Instead, he carried a heterozygous de novo microdeletion 
in 9q31.2, which we estimated to be extremely rare (AF 
below 1/200 000). The deletion encompassed loci of six 
protein-coding genes (FKTN, TAL2, TMEM38B, ZNF462, 
RAD23B, and KLF4).
The deletion was 2.38 Mb in size and the 5’ breakpoint 
broke FKTN in the first intron. However, to the best of our 
knowledge, FKTN is not implicated in KS or CHH (37, 38). 
Haploinsufficiency of ZNF462 is associated with Weiss–
Kruszka syndrome (3), the most typical symptoms of 
which include developmental delay, ptosis, metopic ridge, 
facial asymmetry, corpus callosum dysgenesis, down-
slanting palpebral fissures, arched eyebrows, epicanthal 
folds, short upturned nose with a bulbous tip, marked 
cupid bow/wide philtrum, low set ears, hypertelorism, and 
hearing loss (3, 5). Our proband, thus, clearly exhibited 
Weiss–Kruszka syndrome, and several putative links 
could connect ZNF462 and the reproductive system. For 
instance, fibroblast growth factor 8, required for GnRH 
neuron ontogeny, also induces Znf462 expression in the 
chick pre-placodal region, and hypothalamic expression 
of ZNF462 decreases at puberty in non-human primates 
(39, 40). On the other hand, mutations in ZNF462 have 
not been reported to cause delayed puberty or affect 
the sense of smell (3, 4, 5, 6), suggesting that ZNF462 
haploinsufficiency alone is not sufficient to explain the 
KS phenotype. In humans, the strongest GWAS signals 
that associated with the variation in the age at menarche 
were at 9q31.2 (rs2090409), the nearest genes to this 
SNP being TMEM38B, FKTN, TAL2, and ZNF462 (41), 
as well as SNPs rs12684013, rs4452860, and rs7028916 
(42) in the intergenic regions in 9q31.2 (menarche, 
age at, quantitative trait locus 3, i.e. MENAQ3 locus; 
MIM 612883), which were all deleted in our proband. 
In a recent GWAS study, TMEM38B was associated with 
puberty timing in both males and females (43). Moreover, 
despite the putative association of the 9q31.2 region to 
age at menarche and puberty timing in GWAS studies, 
mutations in the genes deleted in our proband have not 
been implicated in CHH or KS.
KS-related phenotypes in our proband and 
representative previously reported patients with 9q31.2 
deletions are shown in Fig. 2 and Supplementary Table 
2. There are two previous deletions that overlap with the 
one encountered in our proband and are associated with 
delayed puberty or CHH (11, 15). Ramineni  et al. reported 
a family, in which a deletion in 9q31.2 segregated with 
delayed puberty. The overlapping region between their 
deletion and that of ours encompassed only one protein-
coding gene, KLF4. KLF4 is coexpressed with SOX10, a 
known KS gene, in the chick neural crest (44), and KLF4 
interacts with β-catenin and inhibits Wnt signaling 
(45) by preventing β-catenin binding to TCF7L2 (46), a 
transcription factor implicated in the development of the 
hypothalamus and pituitary (47, 48). The deletion in our 
patient and in the family reported by Ramineni  et al. also 
contained the SNP rs139300691, which is associated with 
the sense of smell (49). The second informative patient, 
originally classified to have delayed puberty by Xu  et al., 
had the onset of puberty at the age of 18 years, and his 
Tanner stage was G2 at the age of 20 in the setting of normal 
gonadotropin levels (11). Thus, he fulfilled the criteria of 
CHH (1). The ~35 kb region shared by our proband and 
Xu’s patient (11) contained only a ribosomal pseudogene 
RNA5SP293 (Fig. 2). This region also contains binding 
sites for ZNF143 (a transcription factor which interacts 
with a puberty-related factor, LIN28B, in neuroblastoma 
cells (50)), JUND (JunD binds to Gnrhr AP-1 site in mouse 
gonadotrope-derived αT3-1 cells (51) and is expressed 
in the mouse olfactory bulb (52)), GATA2 and GATA3 
(crucial for neurogenesis and expressed in the olfactory 
bulbs (53)) and CEBPB (Cebpb in rats is expressed in the 
olfactory bulbs and olfactory ensheathing cells (54) and 
is known to be an upstream transcriptional regulator of 
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Gnrh1 in mice (55)). However, the mechanism by which 
a loss of transcription binding site(s) alone would cause 
disease is difficult to decipher, especially as the closest 
KS candidate gene locus (PALM2AKAP2) is relatively far 
away, 1.8 Mb, downstream from the 3’ breakpoint of the 
deletion. This locus in our patient with KS was, however, 
spared and expressed PALM2AKAP2 efficiently (Fig. 3). 
Moreover, screening a set of Finnish KS patients revealed 
no pathogenic variants in PALM2AKAP2. Of note, 
the cases displayed in Fig. 2 showed wide phenotypic 
variability and we were able to verify KS-related features 
in only a proportion of them (Supplementary Table 2 and 
Supplementary Material).
Taken together, variation in the chromosomal region 
9q31.2 at the population level associates with the variation 
in puberty timing and the sense of smell. Previous rare 
patients with deletions including 9q31.2 have exhibited 
CHH and KS-related phenotypes such as delayed puberty, 
an olfactory bulb defect, and cleft lip and/or palate. We 
describe the first patient with an extremely rare de novo 
deletion in 9q31.2 and KS. ZNF462 haploinsufficiency 
was consistent with the patient’s Weiss–Kruszka syndrome 
but did not explain his KS. In further analyses, he did 
not carry rare sequence variants in known KS genes. Our 
results suggest that patients carrying a microdeletion in 
9q31.2 should be evaluated for the presence of KS and 
KS-related features, and conversely, that KS patients with 
features of Weiss–Kruszka syndrome should be evaluated 
for the presence of a heterozygous 9q31.2 microdeletion.
Supplementary materials
This is linked to the online version of the paper at https://doi.org/10.1530/
EJE-20-1387.
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